Xenoma Inc. – Trademark Portfolio
Entity Type: 03
Xenoma Inc. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 25 (Clothing) — 3 filings in this category. The portfolio also extends into Class 10 (Medical Apparatus) across 7 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include XENOMA and X E N O M A.
6-15, Omoriminami 4-chome,
Ota-ku Tokyo 143-0013
Showing of trademarks Trademarks
Trademark Classifications
Xenoma Inc.'s trademark portfolio spans 7 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Games and playthings; gymnastic and sporting articles; decorations for Christmas trees
Education; providing of training; entertainment; sporting and cultural activities
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Xenoma Inc. have?
Xenoma Inc. has 3 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does Xenoma Inc. file in?
Xenoma Inc. files trademarks across 7 Nice Classification classes. The most active classes are Class 25 (Clothing), Class 10 (Medical Apparatus), Class 42 (Computer & Scientific), Class 28 (Toys & Sporting Goods), Class 41 (Education & Entertainment). Class 25 covers clothing, footwear, headgear.
What are Xenoma Inc.'s most well-known trademarks?
Xenoma Inc.'s registered trademark portfolio includes well-known marks such as XENOMA and X E N O M A. These are among 2 currently registered trademarks in the portfolio.
What is Xenoma Inc.'s trademark registration success rate?
Xenoma Inc. has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.